• ML 348: What the Available Evidence Supports

  2026-10-15

  The APExBIO catalog identifies ML 348 as product SKU B4933, but the available product information does not document a chemical structure, biological target, mechanism, assay readout, or identity-matched research evidence. The scientifically defensible scope is therefore limited to catalog identity and explicit evidence boundaries.

• TMB Substrate for ELISA: What Is Documented

  2026-10-15

  APExBIO lists K1131 as a TMB substrate solution for ELISA, but no identity-matched research paper or product-specific performance data are available in the cited evidence. The documented scientific scope is therefore limited to the reagent’s named role as a chromogenic readout component and to the general distinction between upstream recognition and downstream enzymatic signal generation.

• AS 602801: What the Record Supports

  2026-10-14

  The available APExBIO catalog record identifies AS 602801 as SKU A3189 but supplies no description, mechanism, measurement principle, or identity-matched research evidence. The product listing therefore supports only a limited provenance statement and cannot substantiate biological activity, target engagement, assay performance, selectivity, or study outcomes.

• AP-2α, MGMT and Temozolomide Resistance

  2026-10-14

  A preclinical study links reduced AP-2α expression to elevated MGMT and temozolomide resistance in recurrent glioma models. Its findings support a transcriptional mechanism of resistance, but remain limited by the cell and mouse models and by the absence of clinical validation.

• AG-126 and the Limits of Cross-Model Inference

  2026-10-13

  AG-126 (Tyrphostin AG-126) is described by APExBIO as an ERK1/2 phosphorylation inhibitor, while a separate Advanced Science study links Neuroligin 1 loss in striatal D2-MSNs to repetitive behaviors through PKC-associated neuronal hyperactivation. The supplied evidence does not establish that AG-126 affects this autism-related mouse model or repetitive behavior.

• Chlorpromazine HCl: Evidence and Boundaries

  2026-10-13

  Chlorpromazine HCl is a phenothiazine dopamine receptor antagonist with established relevance to neuropharmacology studies and psychotic disorder research. The supplied 2024 study provides evidence that alternating-current electrical stimulation can increase magnetic nanoparticle uptake in several cancer-cell models, but it does not test chlorpromazine HCl. Any connection between the drug’s pharmacology and nanoparticle endocytosis therefore remains a research question rather than a demonstrated application.

• What the Wheat GRO-seq Study Shows

  2026-10-12

  The cited STAR Protocols paper presents a conceptual refinement of GRO-seq for studying transcriptional activity in complex wheat genomes. Its central reported result is a 20-fold increase in the proportion of valid data, although the supplied evidence does not establish that Aprotinin or other protease inhibitors contributed to this outcome.

• Ranolazine and HBV: What the Evidence Shows

  2026-10-12

  The supplied evidence does not provide a head-to-head comparison between Ranolazine and hepatitis B virus (HBV) mechanisms. The cited 2025 study supports a model in which HBsAg alters TBK1-linked interferon and autophagy signaling, while APExBIO’s product description frames Ranolazine as an anti-ischemic agent; no supplied evidence connects these pharmacological and virological contexts.

• PRKX, PD-L1 and Immune Heterogeneity in Gastric Cancer

  2026-10-11

  Wang et al. investigate how PRKX may define an immunosuppressive gastric-cancer subtype by stabilizing PD-L1, while also examining its potential association with response to anti-PD-1 therapy. The findings support a mechanistic model linking PRKX, PD-L1 persistence and CD8+ T-cell exhaustion, but the supplied evidence remains primarily preclinical and observational, with important limits on clinical applicability.

• RAB31 and the ESCRT-Independent Exosome Pathway

  2026-10-10

  Wei et al. identify RAB31 as both a marker and functional regulator of an ESCRT-independent exosome pathway. The study links EGFR-dependent RAB31 activation to flotillin-mediated intraluminal vesicle formation and to TBC1D2B–RAB7 control of multivesicular endosome degradation, refining current models of exosome biogenesis.

• Dimetridazole: From Molecule to Measurement

  2026-10-09

  Dimetridazole research spans antimicrobial biology, quorum sensing, and residue analysis. This evidence-focused guide explains what the leading electrochemical sensor study actually establishes, where its findings apply, and how measurement quality shapes interpretation.

• Cy3-dCTP and the Science of Enzyme Access

  2026-10-09

  Cy3-dCTP enables direct fluorescent labeling of DNA and cDNA, but signal quality also depends on polymerase accessibility and substrate context. This article interprets Cyanine 3-deoxycytidine triphosphate alongside new evidence on ordered DNA interfaces, clarifying what the research supports—and what remains unproven.

• Chlorpromazine and Hepatic Nanoparticle Research

  2026-10-08

  This source-grounded overview separates established chlorpromazine pharmacology from a 2026 ACS Nano study of PEGylated iron oxide nanoparticle interactions with liver cells. It reviews the study’s conceptual design, reported biodistribution and cellular-uptake findings, evidence strength, limitations, and the boundaries of applying those findings to chlorpromazine, chlorpromazine hydrochloride, or broader antipsychotic and nanomedicine research.

• LIDAR: Post-Transcriptional Synthetic Receptors

  2026-10-08

  The 2025 Nature Chemical Biology study introduces LIDAR, a modular synthetic-receptor platform that converts ligand-dependent molecular proximity into RNA editing and post-transcriptional output. Its reported compatibility with multiple receptor architectures, orthogonal inputs, spatial patterning, compact encoding, and synthetic mRNA delivery expands the design space beyond transcriptionally actuated receptors, while remaining a proof-of-concept platform rather than a demonstrated therapeutic system.

• UBC9, PINK1 SUMOylation, and Mitophagy in PD

  2026-10-07

  A 2026 study links the SUMO-conjugating enzyme UBC9 to PINK1 modification, mitochondrial quality control, oxidative stress, and neurotoxic Parkinson’s disease models. Its findings support a mechanistic relationship between UBC9 activity and PINK1-dependent mitophagy, while remaining preclinical because the evidence comes from engineered cell systems and mice rather than human disease cohorts.

8639 records 1/576 page Next 12345 下5页 Last page